Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

par Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Publié 2021

Genomic landscape of gliosarcoma: distinguishing features and targetable alterations

par Mark M. Zaki, Leila A. Mashouf, Eleanor Woodward, Pinky Langat, Saksham Gupta, Ian F. Dunn, Patrick Y. Wen, Brian V. Nahed, Wenya Linda Bi
Publié 2021

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

par Shiliang Huang, Joel E. Michalek, David A. Reardon, Patrick Y. Wen, John R. Floyd, Peter T. Fox, Geoffrey D. Clarke, Paul A. Jerabek, Kathleen M. Schmainda, Mark Muzi, Hyewon Hyun, Eudocia Quant Lee, Andrew J. Brenner
Publié 2021

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

par Ovidiu C. Andronesi, Isabel C. Arrillaga-Romany, K. Ina Ly, Wolfgang Bogner, Eva M. Ratai, Kara Reitz, A. John Iafrate, Jorg Dietrich, Elizabeth R. Gerstner, Andrew S. Chi, Bruce R. Rosen, Patrick Y. Wen, Daniel P. Cahill, Tracy T. Batchelor
Publié 2018

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with surviva...

par Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor
Publié 2017